A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients with Hypertriglyceridemia

American Journal of Cardiology

Volumn 117, Issue 9, 2016, Pages 1444-1448

  Karlson, Björn W ^a,b   Palmer, Michael K ^c   Nicholls, Stephen J ^d   Lundman, Pia ^e   Barter, Philip J ^f  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e DANDERYD HOSPITAL   (Sweden)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; FACTUAL DATABASE;

AGED; ATORVASTATIN CALCIUM; CHOLESTEROL, LDL; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; ROSUVASTATIN CALCIUM; SIMVASTATIN; TRIGLYCERIDES;

EID: 84960834625     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.02.011     Document Type: Article

References (27)

1. N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, S. Bingham, S.M. Boekholdt, K.T. Khaw, and V. Gudnason Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458
2. N. Sarwar, M.S. Sandhu, S.L. Ricketts, A.S. Butterworth, E. Di Angelantonio, S.M. Boekholdt, W. Ouwehand, H. Watkins, N.J. Samani, D. Saleheen, D. Lawlor, M.P. Reilly, A.D. Hingorani, P.J. Talmud, and J. Danesh Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies Lancet 375 2010 1634 1639
3. A. Varbo, M. Benn, A. Tybjaerg-Hansen, A.B. Jorgensen, R. Frikke-Schmidt, and B.G. Nordestgaard Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 2013 427 436
4. B.G. Nordestgaard, and A. Varbo Triglycerides and cardiovascular disease Lancet 384 2014 626 635
5. M. Miller, C.P. Cannon, S.A. Murphy, J. Qin, K.K. Ray, and E. Braunwald Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 51 2008 724 730
6. R.A. Hegele, H.N. Ginsberg, M.J. Chapman, B.G. Nordestgaard, J.A. Kuivenhoven, M. Averna, J. Boren, E. Bruckert, A.L. Catapano, O.S. Descamps, G.K. Hovingh, S.E. Humphries, P.T. Kovanen, L. Masana, P. Pajukanta, K.G. Parhofer, F.J. Raal, K.K. Ray, R.D. Santos, A.F. Stalenhoef, E. Stroes, M.R. Taskinen, A. Tybjaerg-Hansen, G.F. Watts, and O. Wiklund The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management Lancet Diabetes Endocrinol 2 2014 655 666
7. L. Berglund, J.D. Brunzell, A.C. Goldberg, I.J. Goldberg, F. Sacks, M.H. Murad, and A.F. Stalenhoef Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 97 2012 2969 2989
8. A.L. Catapano, Z. Reiner, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, and D. Wood ESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
9. M.J. Chapman, H.N. Ginsberg, P. Amarenco, F. Andreotti, J. Boren, A.L. Catapano, O.S. Descamps, E. Fisher, P.T. Kovanen, J.A. Kuivenhoven, P. Lesnik, L. Masana, B.G. Nordestgaard, K.K. Ray, Z. Reiner, M.R. Taskinen, L. Tokgozoglu, A. Tybjaerg-Hansen, and G.F. Watts Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
10. S.J. Nicholls, G. Brandrup-Wognsen, M. Palmer, and P.J. Barter Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER) Am J Cardiol 105 2010 69 76
11. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, and A.M. Skene Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
12. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, J. Shepherd, and N.K. Wenger Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
13. J.C. Fruchart, F.M. Sacks, M.P. Hermans, G. Assmann, W.V. Brown, R. Ceska, M.J. Chapman, P.M. Dodson, P. Fioretto, H.N. Ginsberg, T. Kadowaki, J.M. Lablanche, N. Marx, J. Plutzky, Z. Reiner, R.S. Rosenson, B. Staels, J.K. Stock, R. Sy, C. Wanner, A. Zambon, and P. Zimmet The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient Diab Vasc Dis Res 5 2008 319 335
14. G.G. Schwartz, M. Abt, W. Bao, D. DeMicco, D. Kallend, M. Miller, H. Mundl, and A.G. Olsson Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins J Am Coll Cardiol 65 2015 2267 2275
15. R.S. Rosenson, M.H. Davidson, B.J. Hirsh, S. Kathiresan, and D. Gaudet Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease J Am Coll Cardiol 64 2014 2525 2540
16. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, E. Miller, V.A. Cain, and J.W. Blasetto Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR∗Trial) Am J Cardiol 92 2003 152 160
17. B.W. Karlson, S.J. Nicholls, P. Lundman, M.K. Palmer, and P.J. Barter Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER Atherosclerosis 228 2013 265 269
18. R.C. Cheung, J.M. Morrell, D. Kallend, C. Watkins, and H. Schuster Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study Int J Cardiol 100 2005 309 316
19. J.M. McKenney, P.H. Jones, M.A. Adamczyk, V.A. Cain, B.S. Bryzinski, and J.W. Blasetto Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial Curr Med Res Opin 19 2003 689 698
20. E.M. Balk, A.H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, and J. Lau Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review Atherosclerosis 189 2006 19 30
21. W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
22. H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse III, L.A. Leiter, P. Linz, W.T. Friedewald, J.B. Buse, H.C. Gerstein, J. Probstfield, R.H. Grimm, F. Ismail-Beigi, J.T. Bigger, D.C. Goff Jr., W.C. Cushman, D.G. Simons-Morton, and R.P. Byington Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
23. P.M. Lavigne, and R.H. Karas The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression J Am Coll Cardiol 61 2013 440 446
24. J. Delgado-Lista, P. Perez-Martinez, J. Lopez-Miranda, and F. Perez-Jimenez Long chain omega-3 fatty acids and cardiovascular disease: a systematic review Br J Nutr 107 Suppl 2 2012 S201 S213
25. R.S. Rosenson Statins: can the new generation make an impression? Expert Opin Emerg Drugs 9 2004 269 279
26. C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, and R. Collins Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
27. J.K. Liao Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol Am J Cardiol 96 2005 24F 33F